modelEntacapone
Extends from Pharmacolibrary.Drugs.ATC.N.N04BX02.
Information
| name: | Entacapone | |
| ATC code: | N04BX02 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 20 | L |
| clearance: | 650 | ml/min |
| other parameters in model implementation | ||
Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), used as an adjunct to levodopa/carbidopa therapy in the management of Parkinson's disease. It is approved and widely used today to prolong the effect of levodopa by blocking its peripheral degradation.
Pharmacokinetics
Pharmacokinetic parameters in healthy adults after a single oral 200 mg dose.
References
Rouru, J, et al., & Scheinin, M (1999). Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. European journal of clinical pharmacology 55(6) 461–467. DOI:10.1007/s002280050657 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10492060
Scott, LJ (2016). Opicapone: A Review in Parkinson's Disease. Drugs 76(13) 1293–1300. DOI:10.1007/s40265-016-0623-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/27498199
Machado, CS, et al., & Fernandes, C (2024). Exploring Nanocarriers for Boosting Entacapone Bioavailability: A Journey through System Characterization and Assessment of Toxicity and Pharmacological and 2D Permeability Paybacks. ACS applied materials & interfaces 16(43) 58299–58312. DOI:10.1021/acsami.4c12372 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39432433
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)